阿尔茨海默病诊断和分期的修订标准的应用：药物开发和临床实践

IF 4.9 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2024-12-14 DOI:10.1002/trc2.70013

Clifford R. Jack, Ana Graf, Samantha C. Burnham, Erin G Doty, Hans J. Moebius, Philip Montenigro, Eric Siemers, Kaycee M. Sink, Leslie M. Shaw, Charlotte Thim Hansen, Kristin R. Wildsmith, Simin Mahinrad, Maria C. Carrillo, Christopher J. Weber

{"title":"阿尔茨海默病诊断和分期的修订标准的应用：药物开发和临床实践","authors":"Clifford R. Jack, Ana Graf, Samantha C. Burnham, Erin G Doty, Hans J. Moebius, Philip Montenigro, Eric Siemers, Kaycee M. Sink, Leslie M. Shaw, Charlotte Thim Hansen, Kristin R. Wildsmith, Simin Mahinrad, Maria C. Carrillo, Christopher J. Weber","doi":"10.1002/trc2.70013","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the Alzheimer's Association (AA) Workgroup represent a significant milestone in the field. These criteria offer objective measures for diagnosing and staging biological AD, bridging the gap between research and clinical care. Although implementation feasibility may vary across regions and settings, improving the availability and accuracy of biomarkers, especially plasma biomarkers, is expected to enhance the applicability of these criteria in clinical practice. The Fall 2023 Alzheimer's Association Research Roundtable (AARR) meeting served as a forum for gathering industry perspectives and feedback on these revised criteria, ensuring that the new criteria inform research, clinical trial design, and clinical care. In this article, we outline a summary of the newly proposed “Revised Criteria for Diagnosis and Staging of AD: AA Workgroup” and provide highlights from the AARR meeting in fall 2023.</p>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government, to review the <i>Revised Criteria for Diagnosis and Staging of AD: AA Workgroup</i>, and gather industry perspectives and feedback on these revised criteria before its publication.</li>\n \n <li>The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the AA's Workgroup represent a significant milestone, offering objective measures for the biological and staging of AD and bridging the gap between research and clinical care.</li>\n \n <li>Improving the availability and accuracy of biomarkers, especially blood-based biomarkers (BBMs) is expected to improve clinical research and enhance the applicability of these criteria in clinical practice.</li>\n </ul>\n </div>\n </section>\n </section>\n </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"10 4","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70013","citationCount":"0","resultStr":"{\"title\":\"Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice\",\"authors\":\"Clifford R. Jack, Ana Graf, Samantha C. Burnham, Erin G Doty, Hans J. Moebius, Philip Montenigro, Eric Siemers, Kaycee M. Sink, Leslie M. Shaw, Charlotte Thim Hansen, Kristin R. Wildsmith, Simin Mahinrad, Maria C. Carrillo, Christopher J. Weber\",\"doi\":\"10.1002/trc2.70013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <p>The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the Alzheimer's Association (AA) Workgroup represent a significant milestone in the field. These criteria offer objective measures for diagnosing and staging biological AD, bridging the gap between research and clinical care. Although implementation feasibility may vary across regions and settings, improving the availability and accuracy of biomarkers, especially plasma biomarkers, is expected to enhance the applicability of these criteria in clinical practice. The Fall 2023 Alzheimer's Association Research Roundtable (AARR) meeting served as a forum for gathering industry perspectives and feedback on these revised criteria, ensuring that the new criteria inform research, clinical trial design, and clinical care. In this article, we outline a summary of the newly proposed “Revised Criteria for Diagnosis and Staging of AD: AA Workgroup” and provide highlights from the AARR meeting in fall 2023.</p>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government, to review the <i>Revised Criteria for Diagnosis and Staging of AD: AA Workgroup</i>, and gather industry perspectives and feedback on these revised criteria before its publication.</li>\\n \\n <li>The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the AA's Workgroup represent a significant milestone, offering objective measures for the biological and staging of AD and bridging the gap between research and clinical care.</li>\\n \\n <li>Improving the availability and accuracy of biomarkers, especially blood-based biomarkers (BBMs) is expected to improve clinical research and enhance the applicability of these criteria in clinical practice.</li>\\n </ul>\\n </div>\\n </section>\\n </section>\\n </div>\",\"PeriodicalId\":53225,\"journal\":{\"name\":\"Alzheimer''s and Dementia: Translational Research and Clinical Interventions\",\"volume\":\"10 4\",\"pages\":\"\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2024-12-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70013\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer''s and Dementia: Translational Research and Clinical Interventions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/trc2.70013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/trc2.70013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

阿尔茨海默病协会（AA）工作组新提出的阿尔茨海默病（AD）诊断和分期的修订标准是该领域的一个重要里程碑。这些标准为诊断和分期生物学AD提供了客观的措施，弥合了研究与临床护理之间的差距。尽管实施的可行性可能因地区和环境而异，但提高生物标志物，特别是血浆生物标志物的可用性和准确性有望增强这些标准在临床实践中的适用性。2023年秋季阿尔茨海默病协会研究圆桌会议（AARR）会议是收集行业对这些修订标准的观点和反馈的论坛，确保新标准为研究、临床试验设计和临床护理提供信息。在本文中，我们概述了新提出的“AD诊断和分期修订标准：AA工作组”的摘要，并提供了2023年秋季AARR会议的亮点。阿尔茨海默病协会研究圆桌会议（AARR）召集了来自工业界、学术界和政府的领导人，审查了AD诊断和分期的修订标准：AA工作组，并在修订标准公布之前收集了业界的观点和反馈。AA工作组新提出的阿尔茨海默病（AD）诊断和分期的修订标准是一个重要的里程碑，为阿尔茨海默病的生物学和分期提供了客观的衡量标准，弥合了研究和临床护理之间的差距。提高生物标志物，特别是血液生物标志物（BBMs）的可用性和准确性有望改善临床研究并增强这些标准在临床实践中的适用性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice

The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the Alzheimer's Association (AA) Workgroup represent a significant milestone in the field. These criteria offer objective measures for diagnosing and staging biological AD, bridging the gap between research and clinical care. Although implementation feasibility may vary across regions and settings, improving the availability and accuracy of biomarkers, especially plasma biomarkers, is expected to enhance the applicability of these criteria in clinical practice. The Fall 2023 Alzheimer's Association Research Roundtable (AARR) meeting served as a forum for gathering industry perspectives and feedback on these revised criteria, ensuring that the new criteria inform research, clinical trial design, and clinical care. In this article, we outline a summary of the newly proposed “Revised Criteria for Diagnosis and Staging of AD: AA Workgroup” and provide highlights from the AARR meeting in fall 2023.

Highlights

The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government, to review the Revised Criteria for Diagnosis and Staging of AD: AA Workgroup, and gather industry perspectives and feedback on these revised criteria before its publication.
The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the AA's Workgroup represent a significant milestone, offering objective measures for the biological and staging of AD and bridging the gap between research and clinical care.
Improving the availability and accuracy of biomarkers, especially blood-based biomarkers (BBMs) is expected to improve clinical research and enhance the applicability of these criteria in clinical practice.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.